Focused On-demand Library for DNA-directed RNA polymerase III subunit RPC6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9H1D9

UPID:

RPC6_HUMAN

Alternative names:

DNA-directed RNA polymerase III subunit F; RNA polymerase III 39 kDa subunit

Alternative UPACC:

Q9H1D9; A8K4C7; O15319

Background:

DNA-directed RNA polymerase III subunit RPC6, also known as the 39 kDa subunit, plays a crucial role in the transcription of DNA into RNA, focusing on small RNAs like 5S rRNA and tRNAs. It is pivotal in sensing and limiting infections by intracellular bacteria and DNA viruses, including varicella zoster virus. This protein binds preferentially to double-stranded DNA, detecting AT-rich DNA involved in the innate immune response.

Therapeutic significance:

The association of this protein with Immunodeficiency 101, a disorder characterized by reactivation of varicella zoster virus, underscores its therapeutic significance. Understanding the role of DNA-directed RNA polymerase III subunit RPC6 could open doors to potential therapeutic strategies for managing this immunologic disorder.